Ariad Pharmaceuticals Inc fka ARIA

[Casablanca]

Mican, thanks as others have noted for the fine summary or your observations on this morning's meeting. I listened to most of it on webcast. The only slight difference in what I heard concerned partnering with another firm in Ariad's drug candidates. It sounded to me as though the interest was not at all strong and there is a sense among senior management and presumably the BOD that Ariad will forge ahead using its own resources. Thus the specter of a raise in 2015 seems increasingly likely if Iclusig revenues don't substantially rise. One other item of interest was the commentary on the investigator sponsored trials experimenting with Iclusig in any number of indications.